Edition:
United States

Recro Pharma Inc (REPH.OQ)

REPH.OQ on NASDAQ Stock Exchange Capital Market

8.56USD
3:59pm EST
Change (% chg)

$-0.05 (-0.58%)
Prev Close
$8.61
Open
$8.68
Day's High
$8.76
Day's Low
$8.51
Volume
28,628
Avg. Vol
25,174
52-wk High
$10.55
52-wk Low
$5.85

Select another date:

Wed, Feb 7 2018

BRIEF-Recro Pharma Estimates Cash And Cash Equivalents About $64 Mln As Of Dec 31

* RECRO PHARMA - ESTIMATES THAT AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $64.0 MILLION Source text for Eikon: (http://bit.ly/2nOPGN7) Further company coverage:

BRIEF-Recro Pharma - ‍Ryan Lake Promoted To CFO

* RECRO PHARMA INC - ‍RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER​ Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co‍​

* RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY‍​

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - ‍has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP​

BRIEF-Recro Pharma reports Q3 revenue $17.1 million

* Recro Pharma Inc - ‍Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million​

BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG

* RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg

* Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Select another date: